



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/920,571	07/31/2001	Roger S. Lasken	17104.0001U2	4875
23859 7590 03/17/2008 NEEDLE & ROSENBERG, P.C. SUITE 1000 999 PEACHTREE STREET ATLANTA, GA 30309-3915			EXAMINER STRZELECKA, TERESA E	
			ART UNIT 1637	PAPER NUMBER
			MAIL DATE 03/17/2008	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

09/920,571

**Applicant(s)**

LASKEN ET AL.

**Examiner**

TERESA E. STRZELECKA

**Art Unit**

1637

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 27 December 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1, 5-9, 14, 20, 22-25, 27, 29, 35-39, 41, 42, 44-49, 51-53, 55-59 and 69-84 is/are pending in the application.
- 4a) Of the above claim(s) 74, 76-82 and 84 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 5-9, 14, 20, 22-25, 27, 29, 35-39, 41, 42, 44-49, 51-53, 55-59, 69-73, 75 and 83 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-846)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 1/2/08; 2/19/08
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### DETAILED ACTION

1. This office action is in response to an amendment filed December 27, 2007. Claims 1, 5-9, 14, 20, 22-25, 27, 29, 35-39, 41, 42, 44-49, 51-53, 55-59 and 69-84 were previously pending, with claims 74, 76-82 and 84 withdrawn from consideration. Applicants did not amend any claims.
2. Applicants' arguments were considered to be persuasive and therefore all of the previously presented rejections are withdrawn. This office action is made non-final because of new grounds for rejection.

### *Information Disclosure Statement*

3. The information disclosure statements filed January 2, 2008 and February 19, 2008 fail to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because it does not conform to the format required by MPEP 609.04(a) (see below):

“37 CFR 1.98(a)(1) also requires that each page of the list include a heading that clearly indicates that the list is an IDS. Since the Office treats an IDS submitted by the applicant differently than information submitted by a third-party (e.g., the Office may discard any non-compliant third-party submission under 37 CFR 1.99), a heading on each page of the list to indicate that the list is an IDS would promote proper treatment of the IDS submitted by the applicant and reduce handling errors.

**37 CFR 1.98(b)** requires that each item of information in an IDS be identified properly. U.S. patents must be identified by the inventor, patent number, and issue date. U.S. patent application publications must be identified by the applicant, patent application publication number, and publication date. U.S. applications must be identified by the inventor, the eight digit application number (the two digit series code and the six digit serial number), and the filing date. If a U.S. application being listed in an IDS has been issued as a patent or has been published, the applicant should list the patent or application publication in the IDS instead of the application. Each foreign patent or published foreign patent application must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application. Each publication must be identified by publisher, author (if any), title, relevant pages of the publication, and date and place of publication. The date of publication supplied must include at least the month and year of publication, except that the year of publication (without the month) will be accepted if the applicant points out in the information disclosure statement that the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue. The place of publication refers to the name of the journal, magazine, or other publication in which the information being submitted was published. Pending U.S.

Art Unit: 1637

applications that are being cited can be listed under the non-patent literature section or in a new section appropriately labeled.”

They have been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609.05(a).

***Claim Rejections - 35 USC § 112***

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 20, 22 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 20, 22 and 23 are indefinite over the recitation of “no larger than about x nucleotides”, which is the same as “having less than about x nucleotides”. The phrase “no larger than” typically indicates a maximum point. The phrase “no larger than” however, is contraverted by the term “about” which implies that values above and below 10,000 nucleotides, for example, are permitted. Further, the extent of variance permitted by “about” is unclear in this context, since Applicants did not define what range of values this term corresponds to. Therefore, it is also unclear what range “about 10,000” refers to. A related phrase “at least about” was found to be indefinite by the courts. In Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (CAFC 1991), the CAFC stated, “The district court held claims 4 and 6 of the patent invalid because their

Art Unit: 1637

specific activity limitation of "at least about 160,000" was indefinite". After review, the CAFC states "We therefore affirm the district court's determination on this issue." Thus, the CAFC found the phrase "at least about" indefinite where the metes and bounds of the term were not defined in the specification.

### ***Claim Interpretation***

6. Applicants defined the term "degenerate primers" on page 6, lines 16-21 as follows:

"Degenerate refers to an oligonucleotide in which one or more of the nucleotide positions is occupied by more than one base, i.e., a mixture of oligonucleotides of defined length in which one or more positions of an individual member of the mixture is occupied by a base selected at random from among more than one possibilities for that position." Therefore totally random primers are also degenerate primers.

7. In view of the indefiniteness of the term "no larger than about", any numerical value of the number of nucleotides is considered to anticipate this term.

### ***Claim Rejections - 35 USC § 102***

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 1, 5-8, 14, 20, 22, 23, 25, 27, 35, 38, 51, 55-58, 69, 70 and 83 are rejected under 35 U.S.C. 102(b) as being anticipated by Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action), as evidenced by Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988).

Regarding claim 1, Navarro et al. teach a method of amplification comprising contacting multiple single stranded non-circular degenerate oligonucleotide primers (P1), one or more single stranded amplification target circles (ATCs), a DNA polymerase and multiple deoxynucleoside triphosphates (dNTPs), under conditions promoting said contacting, wherein each ATC hybridizes to a plurality of said P1 primers, wherein said conditions promote rolling circle replication of said amplification target circle by extension of the P1 primers to form multiple tandem sequence DNA (TS-DNA) products and wherein the TS-DNA is labeled during or following synthesis (Navarro et al. teach contacting multiple hexamer random (= degenerate) primers or degenerate 26 bp primers with a single stranded RNA circles in a presence of a DNA polymerase (AMV reverse transcriptase or Klenow fragment of DNA polymerase I) and multiple dNTPs under conditions promoting rolling circle replication by extension of the primers to form multiple TS-DNA products and wherein the TS-DNA is labeled following synthesis (Fig. 1; page 59, first paragraph; page 60, paragraphs 3-6; page 61, first paragraph; Fig. 2). Navarro et al. do not specifically teach that TS-DNA is obtained in the first step of the viral circles amplification. However, as evidenced by Kool, amplification of small circular DNA or RNA molecules in the range of 15 to 15,000 nucleotides in the presence of a primer and a DNA polymerase results in production of multiple copies of the circular target by rolling circle synthesis (Fig. 1; col. 5, lines 51-67; col. 6, lines 1-33; col. 12, lines 58-67; col. 13, lines 1-19; col. 34, lines 53-67; col. 35, lines 1-20). Kool et al. teach that polymerases useful in the amplification process include Klenow fragment of DNA polymerase I and AMV reverse transcriptase (col. 13, lines 62-67). Therefore, by teaching amplification of circular RNA targets using these two polymerase Navarro et al. inherently teach formation of multimeric copies of the single-stranded circles.)

Regarding claims 5-8, Navarro et al. teach hexamers and 26-mers (Fig. 1; page 60, fifth and sixth paragraph).

Regarding claims 14 and 58, Navarro et al. teach single-stranded RNA circles (page 59, first paragraph).

Regarding claims 20, 22 and 23, Navarro et al. teach RNA targets in the range of 246-357 nucleotides (page 59, first paragraph), anticipating the limitations.

Regarding claim 25, Navarro et al. teach unknown sequence composition of targets (page 60, first paragraph; page 64, second and third paragraph).

Regarding claims 27 and 35, Navarro et al. teach making radioactively-labeled probes (page 65, first paragraph), therefore they inherently teach radiolabeled (= modified) nucleotides.

Regarding claim 38, Navarro et al. teach primers not resistant to exonuclease activity (page 60, fifth and sixth paragraph).

Regarding claim 51, Navarro et al. teach Klenow fragment of DNA polymerase I (Fig. 1; page 60, last paragraph; page 61, first paragraph).

Regarding claims 55, 57 and 58, Navarro et al. teach AMV reverse transcriptase (Fig. 1). As evidenced by Oyama et al., the AMV reverse transcriptase does not have the 3'->5' exonuclease activity (Abstract; page 448, second paragraph).

Regarding claim 56, Navarro et al. teach Taq DNA polymerase (Fig. 1).

Regarding claim 69, Navarro et al. teach isothermal conditions (Fig. 1).

Regarding claim 70, Navarro et al. teach simultaneous hybridization of the primers to ATC (Fig. 1).

Regarding claim 83, Navarro et al. teach labeling with an intercalator (Fig. 2, 3).

***Claim Rejections - 35 USC § 103***

10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

***Rejections based on the Navarro et al. reference***

11. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action), as evidenced by Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988).

Navarro et al. teach using hexamer primers, but do not teach octamers.

However, it would have been obvious to one of ordinary skill in the art to have used any primer length appropriate for the experiment, as noted in *In re Aller*, 105 USPQ 233 at 235,

More particularly, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.

Routine optimization is not considered inventive and no evidence has been presented that the selection of specific primer length was other than routine, that the products resulting from the use of specific primer lengths have any unexpected properties, or that the results should be considered unexpected in any way as compared to the closest prior art.

12. Claims 29, 38, 39, 41, 42, 44-47 and 59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action), as evidenced by Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Oyama et



al. (Anal. Biochem., vol. 172, pp. 444-450, 1988), and Skerra (Nucl. Acids Res., vol. 20, pp. 3551-3554, 1992; cited in the IDS and in the previous office action).

A) The teachings of Navarro et al. are presented above. Navarro et al. teach Klenow fragment DNA of polymerase I and DNA polymerase I (Fig. 1), which have the 3'→5' exonuclease activity. Navarro et al. do not teach using exonuclease-resistant primers or primers with phosphorothioate nucleotides.

B) Skerra teaches that incorporation of phosphorothioate nucleotides into primers protects them from degradation by the 3'→5' exonuclease activity of DNA polymerases (Abstract; page 3553, last paragraph).

Regarding claims 29 and 44-47, Skerra teaches incorporation of phosphorothioate nucleotides into primers at the 3'-end, making them resistant to exonuclease activity (page 3552, fifth paragraph).

Regarding claims 38, 39 and 59, Skerra teaches mixtures of primers resistant to exonuclease activity and not resistant to exonuclease activity and primers resistant to exonuclease activity (page 3553, paragraphs 1-5).

Regarding claims 41 and 42, Skerra teaches 3'→5' exonuclease activity due to DNA polymerase (page 3551, second paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the exonuclease-resistant primers of Skerra in the method of Navarro et al. The motivation to do so, is provided by Skerra (page 3553, last paragraph):

“The results described here clearly demonstrate that the proofreading activity of thermostable DNA polymerases can severely impair with the correct functioning of primers in the amplification of a DNA sequence. This may be the case either by lowering the yield of the PCR product, in some cases even down to no PCR product at all, or by causing non-specific side

products resulting from 3' terminal editing of the primer molecule. Both effects can be completely avoided by the introduction of a single phosphorothioate bond at the very 3' terminus of the primer which seems to effectively protect the oligodeoxynucleotide from 3' terminal exonucleolytic attack."

Therefore, one of ordinary skill in the art faced with the teaching of Skerra related to detrimental effects of 3'→5' exonuclease activity on the primer integrity would be motivated to use exonuclease-resistant primers in the method of Navarro et al., since the amount of starting material in that method was quite limited, therefore improving priming efficiency would increase efficiency of target amplification.

13. Claims 35, 38, 44, 48 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action), as evidenced by Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988), and Ott et al. (Biochemistry, vol. 26, pp. 8237-8241, 1987).

A) The teachings of Navarro et al. are presented above. Navarro et al. teach DNA polymerase I, T4 DNA polymerase and Taq DNA polymerase (Fig. 1), all of which have the 5'→3' exonuclease activity. Navarro et al. do not teach using exonuclease-resistant primers or primers with phosphorothioate nucleotides.

B) Ott et al. teach protection of oligonucleotide primers from the 5'→3' exonuclease activity of a polymerase (Abstract).

Regarding claims 35, 38, 44 and 49, Ott et al. teach incorporation of phosphorothioate nucleotides into 5'-ends of the primers to make the exonuclease resistant (page 8237, second and third paragraph; page 8240, fourth and fifth paragraph).

Regarding claim 48, Ott et al. teach incorporation of more than one phosphorothioate nucleotides into the primer (page 8237, third paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the phosphorothioate nucleotides of Ott et al. in the primers of Navarro et al. The motivation to do, which is provided by Ott et al., would have been that such modification significantly reduces primer degradation by the 5'→3' exonuclease function of the polymerase (page 8240, fifth paragraph). Therefore, faced with the fact that primers annealing around the target RNA molecule would be subject to the 5'→3' exonuclease action of the advancing polymerase (see Fig. 1), one of ordinary skill in the art would be motivated to provide protection from such action according to Ott et al.

***Rejections based on Kool and Navarro et al. references***

14. Claims 1, 5-9, 14, 20, 22-25, 27, 35, 38, 51, 55-58, 69-71, 75 and 83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action), as evidenced by Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988).

A) Regarding claim 1, Kool teaches amplification of short circular DNAs using a primer, dNTPs and a DNA polymerase and producing multiple copies of the circular target by rolling circle synthesis (Fig. 1; col. 5, lines 51-67; col. 6, lines 1-33; col. 12, lines 58-67; col. 13, lines 1-19; col. 34, lines 53-67; col. 35, lines 1-20).

Regarding claims 5-9, Kool teaches primers in the range of 4-50 nucleotides (col. 5, lines 62-64).

Regarding claims 14 and 58, Kool teaches RNA templates (col. 5, lines 59-61).

Regarding claims 20, 22 and 23, Kool teaches circular templates in the range of 15-1500 nucleotides (col. 5, lines 54-57).

Regarding claim 24, Kool teaches bacteriophage DNA (col. 34, lines 55-58).

Art Unit: 1637

Regarding claims 27 and 35, Kool teaches radiolabeled nucleotides (col. 13, lines 50-56), therefore inherently teaches modified nucleotides.

Regarding claim 51, Kool teaches Klenow fragment of DNA polymerase I (col. 13, line 65).

Regarding claims 55 and 56, Kool teaches Taq DNA polymerase (col. 13, lines 66, 67).

Regarding claims 57 and 58, Kool teaches AMV and MuLV reverse transcriptases (col. 13, line 67).

Regarding claim 69, Kool teaches isothermic conditions (col. 13, lines 40-49).

Regarding claims 71 and 75, Kool teaches fluorescently-labeled nucleotides (col. 14, lines 25-31).

B) Kool does not teach using multiple degenerate primers.

C) Regarding claim 1, Navarro et al. teach a method of amplification comprising contacting multiple single stranded non-circular degenerate oligonucleotide primers (P1), one or more single stranded amplification target circles (ATCs), a DNA polymerase and multiple deoxynucleoside triphosphates (dNTPs), under conditions promoting said contacting, wherein each ATC hybridizes to a plurality of said P1 primers, wherein said conditions promote rolling circle replication of said amplification target circle by extension of the P1 primers to form multiple tandem sequence DNA (TS-DNA) products and wherein the TS-DNA is labeled during or following synthesis (Navarro et al. teach contacting multiple hexamer random (= degenerate) primers or degenerate 26 bp primers with a single stranded RNA circles in a presence of a DNA polymerase (AMV reverse transcriptase or Klenow fragment of DNA polymerase I) and multiple dNTPs under conditions promoting rolling circle replication by extension of the primers to form multiple TS-DNA products and wherein the TS-DNA is labeled following synthesis (Fig. 1; page 59, first paragraph; page 60, paragraphs 3-6; page 61, first paragraph; Fig. 2). Navarro et al. do not specifically teach that TS-DNA is obtained

Art Unit: 1637

in the first step of the viral circles amplification. However, as evidenced by Kool, amplification of small circular DNA or RNA molecules in the range of 15 to 15,000 nucleotides in the presence of a primer and a DNA polymerase results in production of multiple copies of the circular target by rolling circle synthesis (Fig. 1; col. 5, lines 51-67; col. 6, lines 1-33; col. 12, lines 58-67; col. 13, lines 1-19; col. 34, lines 53-67; col. 35, lines 1-20). Kool et al. teach that polymerases useful in the amplification process include Klenow fragment of DNA polymerase I and AMV reverse transcriptase (col. 13, lines 62-67). Therefore, by teaching amplification of circular RNA targets using these two polymerase Navarro et al. inherently teach formation of multimeric copies of the single-stranded circles.)

Regarding claims 5-8, Navarro et al. teach hexamers and 26-mers (Fig. 1; page 60, fifth and sixth paragraph).

Regarding claims 14 and 58, Navarro et al. teach single-stranded RNA circles (page 59, first paragraph).

Regarding claims 20, 22 and 23, Navarro et al. teach RNA targets in the range of 246-357 nucleotides (page 59, first paragraph), anticipating the limitations.

Regarding claim 25, Navarro et al. teach unknown sequence composition of targets (page 60, first paragraph; page 64, second and third paragraph).

Regarding claims 27 and 35, Navarro et al. teach making radioactively-labeled probes (page 65, first paragraph), therefore they inherently teach radiolabeled (= modified) nucleotides.

Regarding claim 38, Navarro et al. teach primers not resistant to exonuclease activity (page 60, fifth and sixth paragraph).

Regarding claim 51, Navarro et al. teach Klenow fragment of DNA polymerase I (Fig. 1; page 60, last paragraph; page 61, first paragraph).

Regarding claims 55, 57 and 58, Navarro et al. teach AMV reverse transcriptase (Fig. 1). As evidenced by Oyama et al., the AMV reverse transcriptase does not have the 3'->5' exonuclease activity (Abstract; page 448, second paragraph).

Regarding claim 56, Navarro et al. teach Taq DNA polymerase (Fig. 1).

Regarding claim 69, Navarro et al. teach isothermal conditions (Fig. 1).

Regarding claim 70, Navarro et al. teach simultaneous hybridization of the primers to ATC (Fig. 1).

Regarding claim 83, Navarro et al. teach labeling with an intercalator (Fig. 2, 3).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used multiple degenerate primers of Navarro et al. in the method of amplification of circular nucleic acid targets of Kool with a reasonable expectation of success. The motivation to do so, provided by Navarro et al., would have been that using degenerate primers allowed amplification of targets with unknown sequences and their cloning using minimum amounts of starting RNA (page 60, second paragraph). Further, as the conditions used by Navarro et al. are conditions which promote rolling circle amplification, as evidenced by Kool, the presence of amplified sequences in the method of Navarro et al. indicates that using multiple primers was not detrimental to the amplification process.

The motivation to use rolling circle synthesis in the amplification of circular targets such as the one of Navarro et al. is provided by Kool (col. 8, lines 41-67):

“The rolling circle method is advantageous for many reasons including the following: (1) it allows optimum production of single-stranded oligonucleotides, unlike PCR and cloning; (2) it uses lower amounts of nucleotide units in the synthesis as compared to DNA synthesizers; (3) it requires only a catalytic amount of circular template and, optionally, primer (PCR to produce DNA

Art Unit: 1637

oligomers requires stoichiometric amounts of primer); (4) it produces oligomers having clean, well-defined ends (unlike runoff transcription); (5) it is more efficient than single-stranded PCR amplification or runoff transcription because the polymerase enzyme is not required to associate and dissociate from the template in cycles; (6) expensive thermal cyclers and thermostable polymerases are not required; (7) it is possible to make DNA and RNA oligomers and analogs by this method using the same templates; (8) it is better suited for synthesis of circular oligonucleotides; (9) it allows for production in very large batches (hundreds or thousands of grams); (10) it does not use organic solvents or potentially toxic reagents; (11) fewer errors in the sequences are made (machine-synthesized DNA contains structural errors about every 50-100 bases or so, whereas enzyme methods make errors at the rate of about 1 in 10.sup.4 -10.sup.8 bases); and (12) the product generally needs relatively little purification (perhaps gel filtration or dialysis) because only small amounts of template and polymerase are needed to produce large amounts of oligomer.”

Therefore one of ordinary skill in the art would have been motivated to combine the methods of Kool and Navarro et al. for the purpose of amplification of unknown circular target sequences from small amounts of starting material for reasons stated by Kool and Navarro et al.

15. Claims 29, 35-39, 44, 45, 48, 49 and 51-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action) (as evidenced by Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988)), as applied to claim 1 above, and further in view of Lizardi (5,854,033 A; cited in the previous office action) and Blanco et al. (J. Biol. Chem., vol. 264, pp. 8935-8940, 1989; cited in the IDS).

A) The teachings of Kool and Navarro et al. are presented above. They do not teach exonuclease-resistant primers or phosphorothioate nucleotides, or  $\Phi$ 29 DNA polymerase.

B) Lizardi teaches rolling circle amplification of circular targets (Abstract; col. 2, lines 48-67; col. 3, lines 1-7).

Regarding claims 29 and 35, Lizardi teaches phosphorothioate nucleotides (=modified nucleotides) in the amplification (col. 10, lines 24-28; col. 13, lines 27-31).

Regarding claims 36 and 37, Lizardi teaches oligonucleotides attached to solid support, including glass (col. 14, lines 34-43, 65-67; col. 15, lines 1-10).

Regarding claims 38 and 39, Lizardi teaches primers which include modified nucleotides to make them exonuclease-resistant (col. 10, lines 24-28; col. 13, lines 27-31).

Regarding claims 44 and 45, Lizardi teaches that phosphorothioate nucleotides are positioned at the 5'-end of the primer to make it exonuclease-resistant (col. 10, lines 24-28; col. 13, lines 27-31). Therefore Lizardi anticipates the limitations of an exonuclease-resistant primer containing at least one nucleotide which makes it resistant to exonuclease activity, a modified nucleotide and a phosphorothioate nucleotide.

Regarding claim 48, Lizardi teaches three or four phosphorothioate nucleotides (col. 10, lines 24-28; col. 13, lines 27-31).

Regarding claim 49, Lizardi teaches the phosphorothioate nucleotides being at the 5' end of the primer (col. 10, lines 24-28; col. 13, lines 27-31).

Regarding claims 51 and 52, Lizardi teaches the following DNA polymerases to be used: bacteriophage  $\phi$  29 DNA polymerase, phage M2 DNA polymerase, VENT DNA polymerase, Klenow fragment of DNA polymerase I, T5 DNA polymerase, PRD1 DNA polymerase, T4 DNA polymerase holoenzyme (col. 17, lines 66-67, col. 18, lines 1-11). Therefore, since the claim language links 3', 5'-exonuclease activity with these enzymes, and Lizardi specifically teaches them, Lizardi inherently teaches polymerases with 3'  $\rightarrow$  5' exonuclease activity.



Regarding claim 53, Lizardi teaches bacteriophage  $\phi$  29 DNA polymerase (col. 17, lines 66-67, col. 18, lines 1-11) and exonuclease-resistant primers (col. 10, lines 24-28; col. 13, lines 27-31).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the phosphorothioate nucleotides of Lizardi in the primers of Kool and Navarro et al. The motivation to do so, provided by Lizardi, would have been that using primers with such nucleotides prevents their degradation by exonucleases (col. 10, lines 24-27). Since most polymerases cited by Lizardi as suitable for the method have 5'  $\rightarrow$  3' exonuclease activity, inclusion of the exonuclease-protective nucleotides in the primers prevented their degradation as well as the degradation of amplification products.

It would have been *prima facie* obvious to have used the  $\phi$  29 DNA polymerase of Lizardi in the method of rolling circle amplification of Kool and Navarro et al. The motivation to do so, provided by Blanco et al. , would have been that bacteriophage  $\phi$  29 DNA polymerase was highly processive and did not require any other proteins for efficient rolling circle synthesis of fragments greater than 70 kilobases (Abstract).

16. Claims 29, 35, 38, 39, 41, 42, 44-47 and 59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action) (as evidenced by Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988)), as applied to claim 1 above, and further in view of Skerra (Nucl. Acids Res., vol. 20, pp. 3551-3554, 1992; cited in the IDS and in the previous office action).

A) The teachings of Kool and Navarro et al. are presented above. Navarro et al. and Kool teach Klenow fragment DNA of polymerase I and DNA polymerase I (Fig. 1), which have the 3'-

Art Unit: 1637

>5' exonuclease activity. None of the references teaches using 3'→5' exonuclease-resistant primers with phosphorothioate nucleotides.

B) Skerra teaches that incorporation of phosphorothioate nucleotides into primers protects them from degradation by the 3'→5' exonuclease activity of DNA polymerase (Abstract; page 3553, last paragraph).

Regarding claims 29, 35 and 44-47, Skerra teaches incorporation of phosphorothioate nucleotides into primers at the 3'-end, making them resistant to exonuclease activity (page 3552, fifth paragraph).

Regarding claims 38, 39 and 59, Skerra teaches mixtures of primers resistant to exonuclease activity and not resistant to exonuclease activity and primers resistant to exonuclease activity (page 3553, paragraphs 1-5).

Regarding claims 41 and 42, Skerra teaches 3'→5' exonuclease activity due to DNA polymerase (page 3551, second paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the 3'→5' exonuclease-resistant primers of Skerra in the method of Kool and Navarro et al. The motivation to do so is provided by Skerra (page 3553, last paragraph):

"The results described here clearly demonstrate that the proofreading activity of thermostable DNA polymerases can severely impair with the correct functioning of primers in the amplification of a DNA sequence. This may be the case either by lowering the yield of the PCR product, in some cases even down to no PCR product at all, or by causing non-specific side products resulting from 3' terminal editing of the primer molecule. Both effects can be completely avoided by the introduction of a single phosphorothioate bond at the very 3' terminus of the primer which seems to effectively protect the oligodeoxynucleotide from 3' terminal exonucleolytic attack."

Therefore, one of ordinary skill in the art faced with the teaching of Skerra related to detrimental effects of 3'→5' exonuclease activity on the primer integrity would be motivated to use exonuclease-resistant primers in the method of Kool, Navarro et al. and Lizardi, since in case when the amount of starting material is limited improving priming efficiency would increase efficiency of target amplification.

17. Claims 72 and 73 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kool (U.S. Patent No. 6,096,880 A; cited in the IDS) and Navarro et al. (J. Virol. Meth., vol. 56, pp. 59-66, 1996; cited in the previous office action) (as evidenced by Oyama et al. (Anal. Biochem., vol. 172, pp. 444-450, 1988)), as applied to claims 1 and 71 above, and further in view of Waggoner et al. (U.S. Patent No. 5,268,486 A; cited in the previous office action).

A) The teachings of Kool and Navarro et al. are described above. Kool teaches fluorescent labels, but do not teach cyanine dyes.

B) Regarding claims 72 and 73, Waggoner et al. teach cyanine fluorescent dyes (Abstract; col. 13, 14).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the cyanine dyes of Waggoner et al. in the method of labeling TS-DNA of Kool and Navarro et al. The motivation to do so, provided by Waggoner et al., would have been that the dyes were photostable, had high extinction coefficients and high quantum yields (col. 6, lines 11-24).

18. No claims are allowed.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TERESA E. STRZELECKA whose telephone number is (571)272-0789. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Teresa E Strzelecka  
Primary Examiner  
Art Unit 1637

/Teresa E Strzelecka/  
Primary Examiner, Art Unit 1637

March 8, 2008